# Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Study · id `cardio:ct-nct02651870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02651870](<https://clinicaltrials.gov/study/NCT02651870>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02651870

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

## Technical summary

Registry record NCT02651870. Randomized; double masking; primary purpose treatment. Start 2015-04-22 (actual); primary completion 2016-02-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT02651870, source copy `cardio:ctgov-nct02651870-2020-08-25`, retrieved 2026-10-26)
- Started: 2015-04-22 (actual) (ClinicalTrials.gov record NCT02651870, source copy `cardio:ctgov-nct02651870-2020-08-25`, retrieved 2026-10-26)
- Primary completion: 2016-02-25 (actual) (ClinicalTrials.gov record NCT02651870, source copy `cardio:ctgov-nct02651870-2020-08-25`, retrieved 2026-10-26)
- Completion: 2016-02-29 (actual) (ClinicalTrials.gov record NCT02651870, source copy `cardio:ctgov-nct02651870-2020-08-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02651870, source copy `cardio:ctgov-nct02651870-2020-08-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02651870-2020-08-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
- Condition: Hypertension
- Intervention (Drug): Candesartan 16mg
- Intervention (Drug): Amlodipine 5mg
- Intervention (Drug): Amlodipine 10mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: bf33819d0516029733f2388c52fd3e621bb27aa8197f86a6f48d22af0e90aaa2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
